Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LOAN AND SECURITY AGREEMENT - Additional Information (Details)

LOAN AND SECURITY AGREEMENT - Additional Information (Details) - USD ($)				1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Apr. 13, 2031	Oct. 15, 2021	Apr. 14, 2021	Oct. 31, 2021	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021
Debt Instrument [Line Items]
Net carrying value					$ 14,071,000	$ 14,071,000	$ 13,968,000
Term C loan
Debt Instrument [Line Items]
Additional amount required to raise					$ 12,300,000
Loan and security agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 30,000,000.0
Funding based on ability to obtain equity or subordinated debt financing and the achievement of certain clinical milestones			$ 70,000,000.0
Stated interest rate			8.75%
Variable margin rate			0.12%			0.12%
Contractual rate					8.87%	8.87%	8.87%
Non-refundable facility fee			1.00%
Final fee			4.75%
Debt discounts					$ 1,700,000	$ 1,700,000
Financial advisory and legal fees					500,000	500,000
Facility Fee and Final Fee					$ 800,000	$ 800,000
Exit fee on the funded principal balance			4.00%
Percentage of entity's shares held by investors			35.00%
Default interest rate			5.00%
Loan and security agreement \| Term A loan
Debt Instrument [Line Items]
Gross proceeds from issuance of debt			$ 15,000,000.0
Stated interest rate					12.60%	12.60%	12.60%
Total debt discount					$ 1,700,000		$ 1,700,000
Embedded derivative associated with the exit fee and prepayment fee related to the term A loan					400,000
Debt discounts					1,642,000	$ 1,642,000
Fair value of embedded derivatives			354,000
Outstanding principal balance					15,000,000.0	15,000,000.0
Outstanding Final Fee					700,000	700,000
Total contractual payments					15,713,000	15,713,000
Net carrying value					$ 14,071,000	$ 14,071,000
Loan and security agreement \| Term B loan
Debt Instrument [Line Items]
Remaining borrowing capacity			7,500,000
Funding based on ability to obtain equity or subordinated debt financing and the achievement of certain clinical milestones			35,000,000.0
Cash balance requirement			5,000,000.0
Loan and security agreement \| Term C loan
Debt Instrument [Line Items]
Remaining borrowing capacity			7,500,000
Funding based on ability to obtain equity or subordinated debt financing and the achievement of certain clinical milestones			$ 35,000,000.0
Subsequent Event [Member]
Debt Instrument [Line Items]
Net proceeds from the offering				$ 51,700,000
Registered Direct Offering [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Net proceeds from the offering				5,000,000.0
Underwritten Offering \| Subsequent Event [Member]
Debt Instrument [Line Items]
Net proceeds from the offering		$ 46,700,000		$ 46,700,000
Minimum [Member] \| Loan and security agreement
Debt Instrument [Line Items]
Prepayment fee			1.00%
Maximum [Member] \| Loan and security agreement
Debt Instrument [Line Items]
Prepayment fee			3.00%
Forecast \| Loan and security agreement
Debt Instrument [Line Items]
Exit fee	$ 600,000